News: Melanoma

Next Page »

Best hospital depends on cancer type

Thursday, April 23rd, 2015

The idea of a “Best Hospital for Cancer” does not reflect the fact that cancer comprises many different diseases. Jeffery Goldstein, M.D., Ph.D., a resident in the Department of Pathology, Microbiology and Immunology at Vanderbilt, and Vinay Prasad, M.D., MPH, aimed to rank the 50 highest ranked cancer hospitals – from the 2013 U.S. News […]

NCI report shows U.S. cancer deaths on decline

Thursday, April 2nd, 2015

The death rates for most forms of cancer continue to decline at a modest pace among men, women and children in the United States, according to the Annual Report to the Nation on the Status of Cancer 1975 – 2011. The report from the National Cancer Institute, a division of the National Institutes of Health, […]

VICC’s Johnson to study cancer survivorship with immune inhibitor drugs

Thursday, March 19th, 2015

Douglas Johnson, M.D., assistant professor of Medicine, has been named a recipient of the National Comprehensive Cancer Network  (NCCN) Foundation Young Investigator Awards. The two-year grant will provide $150,000 in funding for his research on survivorship among cancer patients who receive drugs called immune checkpoint inhibitors. The formal announcement of the grant awardees was made […]

BlackHawk’s support reaches milestone

Thursday, February 12th, 2015

Country music group BlackHawk recently presented a check for $20,000 to Harold (Hal) Moses, M.D., Ingram Professor of Cancer Research and director emeritus of Vanderbilt-Ingram Cancer Center (VICC), in support of cancer research. Since 2006, the group has raised and donated $100,000 to VICC in remembrance of one of the original members of the multi-platinum […]

Combo therapy may help fight melanoma

Thursday, January 8th, 2015

Two therapies already in clinical development as single agents may work in combination to treat many subtypes of melanoma, a recent study suggests.

Protein “pockets” help ID cancer genes

Tuesday, November 11th, 2014

Somatic mutations, which can occur in any cell except sperm or egg, are not inheritable. Several recent studies have demonstrated that disease-causing mutations commonly alter protein folding, protein stability and protein-protein interactions. It has been difficult, however, to determine which somatic mutations identified in tumor samples “drive” the cancer development and which are just “along […]

Indiana Couple Supports Melanoma Research

Thursday, October 16th, 2014

Vanderbilt-Ingram Cancer Center (VICC) melanoma patient Gerald (Jerry) Schreiber and wife Phyllis organized and hosted the first annual Melanoma Research Golf Classic in Evansville, Indiana. The golf scramble raised $19,000 for VICC melanoma research spearheaded by Igor Puzanov, M.D., MSCI, associate professor of Medicine and director of Melanoma Clinical Research.

Bradfords’ Support Boosts Melanoma Research

Thursday, September 25th, 2014

When something attacks you, you want to attack it back. That’s how Lillian “Tooty” Bradford views her late husband James “Jimmy” Bradford Jr.’s decision to make an initial gift to fund melanoma research at Vanderbilt-Ingram Cancer Center (VICC). The goal: to attack cancerous melanoma with the help of some of the greatest minds and researchers […]

Uncommon BRAF Melanoma Mutation

Wednesday, July 18th, 2012

An uncommon mutation of the BRAF gene in melanoma patients has been found to respond to MEK inhibitor drugs, providing a rationale for routine screening and therapy in melanoma patients who harbor the BRAF L597 mutation. The new study by co-first-authors Kimberly Brown Dahlman, Ph.D., Junfeng Xia, Ph.D., and Katherine Hutchinson, B.S., Vanderbilt-Ingram Cancer Center […]

New Drug Mutes More Melanomas

Thursday, April 26th, 2012

Therapies targeted to a specific mutation in the BRAF gene can significantly reduce tumor burden in metastatic melanoma. But these therapies are not suitable for melanomas lacking the mutation, and even tumors carrying the BRAF mutation eventually become resistant to those therapies. Using human melanoma tumors implanted into mice, Ann Richmond, Ph.D., and colleagues assessed […]